Cantargia AB (publ)

OM:CANTA Stock Report

Market Cap: SEK 1.0b

Cantargia Valuation

Is CANTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CANTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SEK 125.98
Fair Value
96.7% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: CANTA (SEK4.11) is trading below our estimate of fair value (SEK125.98)

Significantly Below Fair Value: CANTA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CANTA?

Key metric: As CANTA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CANTA. This is calculated by dividing CANTA's market cap by their current earnings.
What is CANTA's PE Ratio?
PE Ratio7.3x
EarningsSEK 139.93m
Market CapSEK 1.02b

Price to Earnings Ratio vs Peers

How does CANTA's PE Ratio compare to its peers?

The above table shows the PE ratio for CANTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.8x
SANION Saniona
4.3xn/aSEK 2.4b
BONEX Bonesupport Holding
87.5x49.69%SEK 13.3b
BIOA B BioArctic
27x-12.63%SEK 27.0b
BIOG B BioGaia
32.3x21.89%SEK 10.2b
CANTA Cantargia
7.3x-74.99%SEK 1.0b

Price-To-Earnings vs Peers: CANTA is good value based on its Price-To-Earnings Ratio (7.3x) compared to the peer average (37.8x).

Price to Earnings Ratio vs Industry

How does CANTA's PE Ratio compare vs other companies in the European Biotechs Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CANTA 7.3xIndustry Avg. 16.6xNo. of Companies8PE020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CANTA is good value based on its Price-To-Earnings Ratio (7.3x) compared to the European Biotechs industry average (16.6x).

Price to Earnings Ratio vs Fair Ratio

What is CANTA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CANTA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.3x
Fair PE Ratio64.1x

Price-To-Earnings vs Fair Ratio: CANTA is good value based on its Price-To-Earnings Ratio (7.3x) compared to the estimated Fair Price-To-Earnings Ratio (64.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CANTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 4.11
SEK 8.67
+111.12%
44.52%SEK 14.00SEK 5.00n/a3
Nov ’26SEK 3.51
SEK 8.67
+146.91%
44.52%SEK 14.00SEK 5.00n/a3
Oct ’26SEK 2.80
SEK 6.00
+114.29%
16.67%SEK 7.00SEK 5.00n/a2
Sep ’26SEK 2.63
SEK 6.00
+128.14%
16.67%SEK 7.00SEK 5.00n/a2
Aug ’26SEK 3.24
SEK 6.00
+85.47%
16.67%SEK 7.00SEK 5.00n/a2
Jul ’26SEK 1.41
SEK 5.50
+291.18%
9.09%SEK 6.00SEK 5.00n/a2
Jun ’26SEK 1.39
SEK 5.75
+314.86%
13.04%SEK 6.50SEK 5.00n/a2
May ’26SEK 1.63
SEK 5.85
+258.90%
14.53%SEK 6.70SEK 5.00n/a2
Apr ’26SEK 1.43
SEK 5.85
+309.09%
14.53%SEK 6.70SEK 5.00n/a2
Mar ’26SEK 1.72
SEK 7.23
+320.79%
28.70%SEK 10.00SEK 5.00n/a3
Feb ’26SEK 1.87
SEK 8.33
+344.68%
28.28%SEK 10.00SEK 5.00n/a3
Jan ’26SEK 1.69
SEK 8.33
+393.10%
28.28%SEK 10.00SEK 5.00n/a3
Dec ’25SEK 1.80
SEK 8.33
+363.74%
28.28%SEK 10.00SEK 5.00n/a3
Nov ’25SEK 3.06
SEK 12.33
+303.05%
13.78%SEK 14.00SEK 10.00SEK 3.513
Oct ’25SEK 3.13
SEK 12.33
+294.04%
13.78%SEK 14.00SEK 10.00SEK 2.803
Sep ’25SEK 3.99
SEK 12.67
+217.78%
16.22%SEK 15.00SEK 10.00SEK 2.633
Aug ’25SEK 3.61
SEK 12.67
+251.27%
16.22%SEK 15.00SEK 10.00SEK 3.243
Jul ’25SEK 4.41
SEK 12.67
+187.36%
16.22%SEK 15.00SEK 10.00SEK 1.413
Jun ’25SEK 4.80
SEK 12.67
+163.89%
16.22%SEK 15.00SEK 10.00SEK 1.393
May ’25SEK 3.34
SEK 12.67
+279.70%
16.22%SEK 15.00SEK 10.00SEK 1.633
Apr ’25SEK 3.49
SEK 12.67
+262.94%
16.22%SEK 15.00SEK 10.00SEK 1.433
Mar ’25SEK 2.72
SEK 12.67
+365.69%
16.22%SEK 15.00SEK 10.00SEK 1.723
Feb ’25SEK 3.47
SEK 13.67
+294.08%
24.15%SEK 18.00SEK 10.00SEK 1.873
Jan ’25SEK 3.74
SEK 13.67
+265.61%
24.15%SEK 18.00SEK 10.00SEK 1.693
Dec ’24SEK 3.54
SEK 13.67
+286.50%
24.15%SEK 18.00SEK 10.00SEK 1.803
Nov ’24SEK 3.43
SEK 14.00
+308.40%
26.73%SEK 19.00SEK 10.00SEK 3.063
SEK 8.67
Fair Value
52.6% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/29 21:38
End of Day Share Price 2025/11/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cantargia AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arvid NecanderCarnegie Investment Bank AB
Soo RomanoffEdison Investment Research
Sara NikH.C. Wainwright & Co.